The Management of Testis Cancer

  • Noel W. Clarke
Part of the Springer Specialist Surgery Series book series (SPECIALIST)


Testis cancer presents most commonly as a painless testicular mass but there are a number of other clinical scenarios. Approximately 20% manifest with scrotal pain and 10% will initially experience an acute orchitis.1 The primary imaging modality in the first instance is ultrasound.2 This has a sensitivity approaching 100% in experienced hands but there are circumstances where it is difficult to differentiate orchitis from tumor and in addition, small intratesticular lesions may produce considerable diagnostic uncertainty. Where precise clinical diagnosis is impossible and a lesion is suspicious, open biopsy or orchidectomy may be needed for definitive verification. If biopsy is to be undertaken, it is usually done using the Chevassu technique, bivalving the testis along its long axis on the opposite side to the epididymis. In these circumstances, surgical exploration should always be through the groin and testis conservation should be attempted where possible. It is inevitable that following surgery some lesions will ultimately prove to be benign: this should be explained to the patient preoperatively.


Testicular Cancer Residual Mass Mature Teratoma Testis Cancer Retroperitoneal Lymph Node Dissection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Horwich A, ed. Testicular Cancer—Investigation and Management. 2nd ed. London: Chapman and Hall; 1996Google Scholar
  2. 2.
    EAU Guidelines on Management of Testis Cancer 2008;
  3. 3.
    Heidenreich A et al. Organ sparing surgery for malignant germ cell tumor of the testis. J Urol. 2001;166(6):2161-2165PubMedCrossRefGoogle Scholar
  4. 4.
    Giannarini G et al. Organ-sparing surgery for adult testicular tumours: a systematic review of the literature. Eur Urol. 2010;57:780-790PubMedCrossRefGoogle Scholar
  5. 5.
    Harland SJ et al. Intratubular germ cell neoplasia of the contralateral testis in testicular cancer: defining a high risk group. J Urol. 1998;160(4):1353-1357PubMedCrossRefGoogle Scholar
  6. 6.
    Dieckmann KP et al. Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. Eur Urol. 2007;51(1):175-183PubMedCrossRefGoogle Scholar
  7. 7.
    Krege S et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I+II. Eur Urol. 2008;53(3):478-513PubMedCrossRefGoogle Scholar
  8. 8.
    Heidenreich A et al. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur Urol. 2009;55:217-226PubMedCrossRefGoogle Scholar
  9. 9.
    Read G et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol. 1992;10(11):1762-1768Google Scholar
  10. 10.
    Freedman L et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet. 1987;2(8554):294-298PubMedCrossRefGoogle Scholar
  11. 11.
    Sternberg CN. The management of stage I testis cancer. Urol Clin North Am. 1998;25(3):435-449PubMedCrossRefGoogle Scholar
  12. 12.
    Albers P. Management of stage I testis cancer. Eur Urol. 2007;51(1):34-43PubMedCrossRefGoogle Scholar
  13. 13.
    Heidenreich A et al. J Urol. 2003;169:1710-1714Google Scholar
  14. 14.
    Tandstad T et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol. 2009;27(19):3263Google Scholar
  15. 15.
    Fossa SD et al. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol. 1999;17(9):3004-3005Google Scholar
  16. 16.
    Jones W et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol. 2005;23(6):1200-1208PubMedCrossRefGoogle Scholar
  17. 17.
    Travis SM. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst. 1997;89(19):1429-1439PubMedCrossRefGoogle Scholar
  18. 18.
    Oliver RTD et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet. 2005;366(9482):293-300CrossRefGoogle Scholar
  19. 19.
    Warde P et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol. 2002;20:4448PubMedCrossRefGoogle Scholar
  20. 20.
    Aparicio J et al. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol. 2005;23:8717-8723PubMedCrossRefGoogle Scholar
  21. 21.
    Carver B et al. Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors. J Clin Oncol. 2007;25(35):5603-5608PubMedCrossRefGoogle Scholar
  22. 22.
    Collette L et al. Impact of the treating institution on survival of patients with “poor-prognosis” metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst. 1999;91(10):839-846Google Scholar
  23. 23.
    Culine S et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol. 2007;18:917PubMedCrossRefGoogle Scholar
  24. 24.
    Motzer RJ et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007;25(3):247-256PubMedCrossRefGoogle Scholar
  25. 25.
    Travis LB et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst. 2005;97(18): 1354-1365PubMedCrossRefGoogle Scholar
  26. 26.
    Belt-Dusebout AW et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2007;25:4370PubMedCrossRefGoogle Scholar
  27. 27.
    Huddart RA et al. J Clin Oncol. 2003;21(8):1513-1523Google Scholar
  28. 28.
    Hinz S et al. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. J Urol. 2008;179(3):936-940PubMedCrossRefGoogle Scholar
  29. 29.
    Schmoll HJ, EGCCCG, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol. 2004;15:1377-1399Google Scholar
  30. 30.
    Hendry WF et al. Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer. 2002;94:1668-1676PubMedCrossRefGoogle Scholar
  31. 31.
    Beck SD et al. The role of postchemotherapy surgery in managing metastatic germ cell tumors. Cancer. 2007;110(12):2601-2603PubMedCrossRefGoogle Scholar
  32. 32.
    Lorch A et al. J Urol. 2010;184(1):168-173Google Scholar
  33. 33.
    Lorch A et al. Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol. 2007;25(19):2778-2784PubMedCrossRefGoogle Scholar
  34. 34.
    Albers P et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol. 2008;26(18):2966-2972PubMedCrossRefGoogle Scholar

Copyright information

© Springer London 2011

Authors and Affiliations

  • Noel W. Clarke
    • 1
  1. 1.Departments of Surgery and UrologyManchester University, Christie and Salford Royal HospitalsManchesterUK

Personalised recommendations